Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial
Primary result · Total MI eventsResult — go to the resultRate ratio 0.79 95% CI 0.620–0.998Authors' conclusion
In T2D patients with ASCVD, empagliflozin reduced the risk of MIs, with consistent effects across the two most common etiologies, i.e. type 1 and 2.
Study context
- Population
- People with T2D and CVD (mostly atherosclerotic)
- Participants
- 7,020 people
- Comparison
- Empagliflozin vs placebo
- Primary endpoint
- Total (first plus recurrent) centrally adjudicated fatal and non-fatal MI events
- Follow-up
- Median 3.1 years
Methodological detailsprespecified and post-hoc analyses
- Prespecified and post-hoc analyses
Primary result
Total MI events
Rate ratio
0.79
95% CI 0.620–0.998
P = 0.0486
Empagliflozinvs Placebo
rate ratio 0.79 (95% CI 0.620–0.998); P = 0.0486
As reported in the abstract
- Total myocardial infarction (MIs) (including recurrent)
- 421
- Risk of total MI events reduced with empagliflozin
- 21%
Further findings
| Outcome | Rate ratio (95% CI) | |
|---|---|---|
| Type 1 MI (post hoc) | 0.79 (0.61–1.04) | |
| Type 2 MI (post hoc) | 0.67 (0.41–1.10) | |
| 0.512Rate ratio (log scale) |
- Type 1 MI (post hoc) — Type 1 events
- 299
- Type 2 MI (post hoc) — Type 2 events
- 86
Type 3, 4 and 5 MI events (post hoc)
- Type 3 events
- 26
- Type 4 events
- 19
- Type 5 events
- 1
- MIs could be assigned to > 1 type
Original publication
Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial. Cardiovasc Diabetol. Published 11 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →